Clinical trials: ABPA
Allergic Bronchopulmonary Aspergillosis
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT01857479
- Testing
- Inhaled budesonide, Inhaled amphotericin
- Where
- India
- Volunteers
- 21 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Allergic Bronchopulmonary Aspergillosis
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus.
- Trial name
- NCT00974766
- Testing
- Glucocorticoids
- Where
- India
- Volunteers
- 92 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Thymus and Activation Regulated Chemokine
Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis
This study aims to assess the value of TARC in diagnosis of allergic Bronchopulmonary Aspergillosis.
- Trial name
- NCT03267394
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cystic Fibrosis, Chit1
Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients
Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease in CF Patients. Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to ABPA or persistent…
- Trial name
- NCT01572870
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Cystic Fibrosis,
Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic bronchial inflammation is an important clinical feature in cystic fibrosis. Approximately 10% of patients with cystic fibrosis suffer from Allergic Bronchopulmonary Aspergillosis.
- Trial name
- ABPA (NCT00906568)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Cystic Fibrosis, Fungal Infection
Immune Profiles in CF Fungal Infection
This study is investigating the role of allergic (Th2) inflammation in patients with Cystic Fibrosis (CF) and history of fungal infection and/or Allergic Bronchopulmonary Aspergillosis.
- Conditions
- Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
- Trial name
- NCT04476758
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
- Trial name
- NCT01222273
- Testing
- cholecalciferol (Vitamin D3)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pittsburgh
Allergic Bronchopulmonary Aspergillosis
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT04442269
- Testing
- dupilumab
- Where
- 50 sites in United States, Bulgaria and 8 more
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Bronchopulmonary Aspergillosis
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.
- Trial name
- MIPA (NCT01321827)
- Testing
- Glucocorticoids, Itraconazole
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs.
- Trial name
- ABPA (NCT00585364)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Pulmonary Cystic Fibrosis, ABPA
Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis
In this diagnostic study, the aim is at evaluating the diagnostic accuracy of MRI (Magnetic Resonance Imaging) to detect allergic broncho-pulmonary aspergillosis in patients with cystic fibrosis.
- Trial name
- MRAB (NCT02853175)
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Hôpital Haut Lévêque
Allergic Bronchopulmonary Aspergillosis
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
This is a research project to evaluate the efficacy and safety of two different treatment protocols in Allergic bronchopulmonary Aspergillosis.
- Trial name
- NCT01621321
- Testing
- Prednisolone, Voriconazole
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals